CL2012001102A1 - Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas. - Google Patents

Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.

Info

Publication number: CL2012001102A1
Authority: CL; Chile
Prior art keywords: hexahydrocyclopenta; pyrrol; benzamide; poisoning; cerebral
Prior art date: 2011-05-02

Application number

CL2012001102A

Other languages

English (en)

Inventor

Caryn Trocme-Thibierge

Aurore Sors

Florence Keime-Guibert

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-02

Filing date

2012-04-27

Publication date

2014-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-27 Application filed by Servier Lab filed Critical Servier Lab

2014-06-20 Publication of CL2012001102A1 publication Critical patent/CL2012001102A1/es

Links

MRNMYWNBLVJWKG-GASCZTMLSA-N 4-[3-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]propoxy]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCCCN1C[C@H]2CCC[C@H]2C1 MRNMYWNBLVJWKG-GASCZTMLSA-N 0.000 title 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
230000002490 cerebral effect Effects 0.000 title 1
239000000544 cholinesterase inhibitor Substances 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
208000015122 neurodegenerative disease Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
231100000572 poisoning Toxicity 0.000 title 1
230000000607 poisoning effect Effects 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2012001102A 2011-05-02 2012-04-27 Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas. CL2012001102A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1101347A FR2974729B1 (fr)	2011-05-02	2011-05-02	Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
CL2012001102A1 true CL2012001102A1 (es)	2014-06-20

Family

ID=44351420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012001102A CL2012001102A1 (es)	2011-05-02	2012-04-27	Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.

Country Status (29)

Country	Link
US (3)	US8940785B2 (es)
EP (1)	EP2520296A1 (es)
JP (1)	JP2012232978A (es)
KR (2)	KR101493757B1 (es)
CN (1)	CN102764439A (es)
AP (1)	AP3104A (es)
AR (1)	AR086146A1 (es)
BR (1)	BR102012010244A2 (es)
CA (1)	CA2775624A1 (es)
CL (1)	CL2012001102A1 (es)
CR (1)	CR20120192A (es)
CU (1)	CU20120064A7 (es)
EA (1)	EA020987B1 (es)
EC (1)	ECSP12011862A (es)
FR (1)	FR2974729B1 (es)
GE (1)	GEP20146076B (es)
MA (1)	MA34776B1 (es)
MX (1)	MX2012005103A (es)
NI (1)	NI201200070A (es)
PE (1)	PE20130016A1 (es)
PH (1)	PH12012000088A1 (es)
RU (1)	RU2013153140A (es)
SG (2)	SG2014010904A (es)
SV (1)	SV2012004203A (es)
TN (1)	TN2012000177A1 (es)
TW (1)	TW201247200A (es)
UY (1)	UY34050A (es)
WO (1)	WO2012150412A1 (es)
ZA (1)	ZA201203163B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2976285B1 (fr) *	2011-06-08	2013-05-24	Servier Lab	Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
JO3579B1 (ar)	2014-09-26	2020-07-05	Luc Therapeutics Inc	مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
LT3500253T (lt)	2016-08-18	2020-08-25	Suven Life Sciences Limited	Histamino-3 receptoriaus inversinių agonistų derinys su acetilcholinesterazės inhibitoriais
PT3500306T (pt) *	2016-08-18	2020-09-29	Suven Life Sciences Ltd	Combinação tripla de agonistas inversos do recetor de histamina-3, inibidores da acetilcolinesterase e antagonista do recetor nmda
CN108371660B (zh) *	2017-12-14	2020-03-10	五邑大学	一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11690849B2 (en)	2019-04-12	2023-07-04	LA PharmaTech Inc.	Method of treating dementia
US11938139B2 (en)	2019-04-12	2024-03-26	LA PharmaTech Inc.	Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en)	2019-04-12	2023-09-05	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of insomnia
AU2019446955A1 (en) *	2019-05-21	2021-12-23	La Pharma Tech Inc.	Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2866647B1 (fr) *	2004-02-20	2006-10-27	Servier Lab	Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20070015598A (ko) *	2004-04-28	2007-02-05	다케다 야쿠힌 고교 가부시키가이샤	융합 퀴놀린 유도체 및 이의 용도
TW200823204A (en) *	2006-10-17	2008-06-01	Arena Pharm Inc	Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) *	2007-03-30	2008-12-01	Targacept Inc	Sub-type selective azabicycloalkane derivatives
WO2009048101A1 (ja) *	2007-10-10	2009-04-16	Takeda Pharmaceutical Company Limited	アミド化合物
US20090221554A1 (en) *	2008-02-28	2009-09-03	Zenyaku Kogyo Kabushiki Kaisha	Method of treating cognitive impairment
FR2937251B1 (fr) *	2008-10-16	2011-03-18	Servier Lab	Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) *	2009-12-09	2011-12-23	Servier Lab	Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2011
- 2011-05-02 FR FR1101347A patent/FR2974729B1/fr not_active Expired - Fee Related
2012
- 2012-04-17 PH PH1/2012/000088A patent/PH12012000088A1/en unknown
- 2012-04-18 TN TNP2012000177A patent/TN2012000177A1/fr unknown
- 2012-04-19 CR CR20120192A patent/CR20120192A/es unknown
- 2012-04-23 EA EA201200527A patent/EA020987B1/ru not_active IP Right Cessation
- 2012-04-23 AP AP2012006232A patent/AP3104A/xx active
- 2012-04-23 PE PE2012000533A patent/PE20130016A1/es not_active Application Discontinuation
- 2012-04-23 CU CU2012000064A patent/CU20120064A7/es unknown
- 2012-04-25 CA CA2775624A patent/CA2775624A1/fr not_active Abandoned
- 2012-04-27 SG SG2014010904A patent/SG2014010904A/en unknown
- 2012-04-27 AR ARP120101487A patent/AR086146A1/es unknown
- 2012-04-27 NI NI201200070A patent/NI201200070A/es unknown
- 2012-04-27 SG SG2012031282A patent/SG185240A1/en unknown
- 2012-04-27 CL CL2012001102A patent/CL2012001102A1/es unknown
- 2012-04-30 TW TW101115413A patent/TW201247200A/zh unknown
- 2012-04-30 MA MA34823A patent/MA34776B1/fr unknown
- 2012-04-30 GE GEAP201212686A patent/GEP20146076B/en unknown
- 2012-04-30 MX MX2012005103A patent/MX2012005103A/es not_active Application Discontinuation
- 2012-04-30 BR BRBR102012010244-7A patent/BR102012010244A2/pt not_active IP Right Cessation
- 2012-05-01 US US13/461,063 patent/US8940785B2/en not_active Expired - Fee Related
- 2012-05-01 JP JP2012104353A patent/JP2012232978A/ja active Pending
- 2012-05-02 CN CN2012101341396A patent/CN102764439A/zh active Pending
- 2012-05-02 RU RU2013153140/04A patent/RU2013153140A/ru not_active Application Discontinuation
- 2012-05-02 UY UY0001034050A patent/UY34050A/es unknown
- 2012-05-02 EP EP12166348A patent/EP2520296A1/fr not_active Withdrawn
- 2012-05-02 EC ECSP12011862 patent/ECSP12011862A/es unknown
- 2012-05-02 ZA ZA2012/03163A patent/ZA201203163B/en unknown
- 2012-05-02 KR KR20120046521A patent/KR101493757B1/ko not_active Expired - Fee Related
- 2012-05-02 WO PCT/FR2012/050971 patent/WO2012150412A1/fr not_active Ceased
- 2012-05-02 SV SV2012004203A patent/SV2012004203A/es unknown
2014
- 2014-03-31 KR KR1020140037996A patent/KR20140051200A/ko not_active Withdrawn
- 2014-11-25 US US14/553,167 patent/US20150080378A1/en not_active Abandoned
- 2014-11-26 US US14/554,778 patent/US20150080379A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR086146A1 (es)	2013-11-20
PH12012000088A1 (en)	2023-12-18
SV2012004203A (es)	2012-08-23
KR20130130238A (ko)	2013-12-02
UY34050A (es)	2012-11-30
SG185240A1 (en)	2012-11-29
KR101493757B1 (ko)	2015-02-16
MA34776B1 (fr)	2014-01-02
ECSP12011862A (es)	2012-07-31
EA020987B1 (ru)	2015-03-31
FR2974729B1 (fr)	2013-04-19
BR102012010244A2 (pt)	2013-06-18
GEP20146076B (en)	2014-04-10
ZA201203163B (en)	2013-01-30
AP2012006232A0 (en)	2012-04-30
NI201200070A (es)	2012-11-09
US20150080379A1 (en)	2015-03-19
CA2775624A1 (fr)	2012-11-02
TN2012000177A1 (fr)	2013-12-12
RU2013153140A (ru)	2015-06-10
PE20130016A1 (es)	2013-01-26
FR2974729A1 (fr)	2012-11-09
KR20140051200A (ko)	2014-04-30
US20120283244A1 (en)	2012-11-08
AP3104A (en)	2015-01-31
WO2012150412A1 (fr)	2012-11-08
EA201200527A1 (ru)	2012-12-28
TW201247200A (en)	2012-12-01
NZ599633A (en)	2014-02-28
SG2014010904A (en)	2014-05-29
CR20120192A (es)	2012-12-06
EP2520296A1 (fr)	2012-11-07
US20150080378A1 (en)	2015-03-19
CN102764439A (zh)	2012-11-07
CU20120064A7 (es)	2013-12-27
JP2012232978A (ja)	2012-11-29
US8940785B2 (en)	2015-01-27
MX2012005103A (es)	2013-06-05

Publication	Publication Date	Title
CL2012001102A1 (es)	2014-06-20	Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.
CR20130410A (es)	2013-10-17	Compuestos y composiciones como inhibidores de la trk
JO3002B1 (ar)	2016-09-05	مركبات و تركيبات كمثبطات كيناز بروتين
CO6940374A2 (es)	2014-05-09	Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
PT2919796T (pt)	2021-06-02	Utilização de akkermansia para o tratamento de distúrbios metabólicos
BRPI0819241A2 (pt)	2015-05-05	Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
PT2709989T (pt)	2018-03-27	Derivados de quinazolina para o tratamento de infeções virais e outras doenças
CL2013003638A1 (es)	2014-10-10	Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
EP2903613A4 (en)	2016-04-20	INHIBITORS OF IRAQ4 ACTIVITY
BR112013033098B8 (pt)	2021-03-23	inibidores de glicosidade seletivos e usos dos mesmos
BR112016009889A2 (pt)	2017-12-05	?compostos agonistas duplos gip-glp-1 e métodos?
ECSP14013153A (es)	2014-04-30	Compuestos inhibidores de metaloenzimas
BRPI0919004A2 (pt)	2019-09-24	composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
HRP20182043T1 (hr)	2019-04-19	Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
CL2015000096A1 (es)	2015-06-19	Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
SG11201401343YA (en)	2014-08-28	TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
CR20140553A (es)	2015-02-04	Compuestos de fenoxietil piperidina
EP2566520A4 (en)	2014-02-12	METHOD FOR TREATING IL1-MEDIATED INTERFERENCE
CR20140554A (es)	2015-02-04	Compuestos de acido dimetil-benzoico
EP2782566A4 (en)	2016-01-13	L-SERIN COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEEGENERATIVE ILLNESSES AND SUFFERING
EP2720695A4 (en)	2014-11-12	ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES
EP2825173A4 (en)	2015-12-09	CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISEASES AND RIBOSOMAPATHIES
BR112015002275A2 (pt)	2017-07-04	processos e intermediários para a preparação de inibidores da integrase
HK1211586A1 (zh)	2016-05-27	β-分泌酶抑制劑
BR112013033970A2 (pt)	2017-02-14	compostos e combinações farmacêuticas para o tratamento de doenças cerebrais isquêmicas e neurodegenerativas